General Biologics Inc.

General Biologics Inc. is a biotechnology research company located in Cambridge, Massachusetts, registered in the System for Award Management (SAM) since February 2019. As a for-profit corporate entity, the company specializes in developing advanced biological and medical technologies, with a primary focus on engineered proteins and cellular therapies. The company collaborates with prestigious research institutions like Harvard University and works closely with federal agencies such as DARPA and the National Heart, Lung, and Blood Institute to advance innovative biomedical research solutions.

Through federal contract awards, General Biologics Inc. has primarily engaged in Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, specifically with the Defense Advanced Research Projects Agency (DARPA). Their contract work centers on developing advanced cellular therapies, particularly focused on addressing hypoxia challenges for military personnel. The company was awarded a $977,883 Firm Fixed Price STTR Phase II contract to develop "Patterned, Responsive Cellular Therapies Using Novel Mammalian Cellular Regulator Systems." This project involves collaboration with Harvard University and the Air Force Research Laboratory, targeting innovative solutions for fighter pilots experiencing oxygen-related challenges, with the contract set aside specifically for small businesses.

In the federal grant space, General Biologics Inc. has received awards focused on advanced medical research, most notably a $306,658 project grant from the National Heart, Lung, and Blood Institute. This grant supports the development of a tissue-targeted non-thrombotic erythropoietin (EPO) derivative called "EPO-H," designed to help patients with chronic obstructive pulmonary disease (COPD) who also experience anemia. The research aims to create an engineered protein that maintains red blood cell production and tissue-protective capabilities while eliminating dangerous blood clotting side effects. Additionally, the company has participated in sub-grant awards, such as a May 2023 collaboration with the Henry M. Jackson Foundation for the Advancement of Military Medicine, focusing on developing anti-hypoxia proteins for potential military applications, particularly for preventing cognitive damage in fighter pilots experiencing oxygen deficiency.

We engage in corporate partnerships for therapeutic protein engineering, antibody humanization, fusion protein design and construction, extension of serum half-life, and biological insight.